| Literature DB >> 28834750 |
Oliver H Miller1, Andreas Bruns2, Imen Ben Ammar3, Thomas Mueggler2, Benjamin J Hall4.
Abstract
The NMDA receptor (NMDAR) antagonist ketamine elicits a long-lasting antidepressant response in patients with treatment-resistant depression. Understanding how antagonism of NMDARs alters synapse and circuit function is pivotal to developing circuit-based therapies for depression. Using virally induced gene deletion, ex vivo optogenetic-assisted circuit analysis, and in vivo chemogenetics and fMRI, we assessed the role of NMDARs in the medial prefrontal cortex (mPFC) in controlling depression-related behavior in mice. We demonstrate that post-developmental genetic deletion of the NMDAR subunit GluN2B from pyramidal neurons in the mPFC enhances connectivity between the mPFC and limbic thalamus, but not the ventral hippocampus, and reduces depression-like behavior. Using intersectional chemogenetics, we show that activation of this thalamocortical circuit is sufficient to elicit a decrease in despair-like behavior. Our findings reveal that GluN2B exerts input-specific control of pyramidal neuron innervation and identify a medial dorsal thalamus (MDT)→mPFC circuit that controls depression-like behavior.Entities:
Keywords: GluN2B; NMDAR; chemogenetics; depression; ketamine; medial dorsal thalamus; motivation; optogenetics; thalamocortical
Mesh:
Year: 2017 PMID: 28834750 DOI: 10.1016/j.celrep.2017.08.002
Source DB: PubMed Journal: Cell Rep Impact factor: 9.995